



Salariaus Pharmaceuticals to Present During Virtual LD 500 Conference

Webcast presentation scheduled for Tuesday, September 1, 2020

HOUSTON, August 27, 2020 (GLOBE NEWSWIRE) –[Salariaus Pharmaceuticals, Inc.](https://www.salariauspharma.com) (Nasdaq: SLRX), a clinical-stage oncology company targeting cancers caused by dysregulated gene expression, announced today that its Chief Executive Officer, David Arthur, will present during the 2020 LD 500 Conference. The event will take place September 1-4, 2020 via a virtual technology platform.

Mr. Arthur will present an overview of Salariaus' business and highlight its recent corporate and clinical achievements, as well as the anticipated milestones in its clinical program for its lead compound, seclidemstat. Seclidemstat is a reversible LSD1 inhibitor now undergoing two Phase 1/2 clinical trials in Ewing sarcoma, a rare and deadly pediatric bone cancer, and advanced solid tumors (AST). Members of the Salariaus management team will be available to participate in one-on-one virtual meetings with investors who are registered to attend the conference.

Details of Salariaus' presentation are as follows:

Event:	LD 500 Conference
Date:	Tuesday, September 1, 2020
Time:	3:20 PM (ET)
Live Webcast:	https://www.webcaster4.com/Webcast/Page/2019/36538

The live webcast of the presentation will be available by clicking the registration link or visiting the upcoming events section of the Company's website at www.salariauspharma.com. The webcast will also be available for replay on the conference website following the event.

About Salariaus Pharmaceuticals

Salariaus Pharmaceuticals, Inc. is a clinical-stage oncology company targeting cancers caused by dysregulated gene expression and is developing treatments for patients that need them the most. Epigenetics refers to the regulatory system that affects gene expression. Salariaus' lead candidate, seclidemstat, is currently in a Phase 1/2 clinical trial for relapsed/refractory Ewing sarcoma, for which it has received Fast Track Designation, Orphan Drug Designation and Rare Pediatric Disease Designation from the U.S. Food and Drug Administration. Salariaus is also developing seclidemstat for several cancers with high unmet medical need, with a second Phase 1/2 clinical study in advanced solid tumors, including prostate, breast, and ovarian cancers. Salariaus has received financial support from the National Pediatric Cancer Foundation to advance the Ewing sarcoma clinical program and is also the recipient of an \$18.7 million Product Development Award from the Cancer Prevention and Research Institute of Texas (CPRIT). For more information, please visit [salariauspharma.com](http://www.salariauspharma.com).

Forward-Looking Statements

This news release includes forward-looking statements within the meaning of the U.S. federal and Canadian securities laws. These forward-looking statements involve substantial risks and uncertainties, including statements that are based on the current expectations and assumptions of the Company's management. All statements, other than statements of historical facts, included in this press release regarding the Company's plans and objectives, expectations and assumptions of management are forward-looking statements. The use of certain words, including the words "estimate," "project," "intend," "expect," "believe," "anticipate," "will," "plan," "could," "may" and similar expressions are intended to identify forward-looking statements. The Company may not actually achieve the plans, intentions or expectations disclosed in the forward-looking statements and you should not place undue reliance on the Company's forward-looking statements. Various important factors could cause actual results or events to differ materially from those that may be expressed or implied by our forward-looking statements including receipt of regulatory approvals and market conditions. The forward-looking statements are made as of this date and the Company does not undertake any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact

Investor Relations

[Tiberend Strategic Advisors, Inc.](#)

Maureen McEnroe, CFA/Miriam Miller

(212) 375-2664/ 2694

mmcenroe@tiberend.com/mmiller@tiberend.com

Media Relations

[Tiberend Strategic Advisors, Inc.](#)

Johanna Bennett

(212) 375-2686

jbennett@tiberend.com